Management of patients with cirrhosis awaiting liver transplantation

Gut

Volumn 60, Issue 3, 2011, Pages 412-421

  Cárdenas, Andrés ^a   Ginès, Pere ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; CONIVAPTAN; DACLIZUMAB; FUROSEMIDE; LACTITOL; MIDODRINE; NADOLOL; NORFLOXACIN; OCTREOTIDE; PLACEBO; PROPRANOLOL; RIFAXIMIN; SOMATOSTATIN; SPIRONOLACTONE; TERLIPRESSIN; TOLVAPTAN;

ASCITES; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BLEEDING; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS VARICES; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; HYPONATREMIA; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SODIUM RESTRICTION; THIRST; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; UNSPECIFIED SIDE EFFECT; VARIX BLEEDING; WATER DEPRIVATION;

ASCITES; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMANS; HYPONATREMIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; OPPORTUNISTIC INFECTIONS; WAITING LISTS;

EID: 79851515291     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.179937     Document Type: Review

References (114)

1. Starzl TE, Marchioro T, Vonkaulla K, et al. Homotransplantation of the liver in humans. Surg Gynecol Obstet 1963;117:659-76.
2. Starzl TE, Demetris AJ, VanThiel D. Liver transplantation. N Eng J Med 1989;321:1014-22.
3. US transplant. Scientific registry of transplant recipients: Transplant program and OPO-specific reports, 2010. http://www.ustransplant.org (accessed 1 Jun 2010).
4. European liver transplant registry. http://www.eltr.org (accessed 1 Jun 2010).
5. Kamath PS, Kim WR. The Model for End-stage Liver Disease (MELD). Hepatology 2007;45:797-805. (Pubitemid 46450631)
6. Welcome to the 2008 OPTN/ SRTR Annual Report: Transplant Data 1998-2007. Waiting List Outcome Tables. http://www.ustransplant.org (accessed 1 Jun 2010).
7. Waiting time to transplant. http://www.uktransplant.org.uk (accessed 1 Jun 2010).
8. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48(Suppl 1):S20-37.
9. Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006;4:1385-94.
10. Moore KP, Wong F, Ginès P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003;38:258-66. (Pubitemid 36775818)
11. Ginès P, Cárdenas A. The management of ascites and dilutional hyponatremia in cirrhosis. Semin Liver Dis 2008;28:43-58. (Pubitemid 351326532)
12. Perez-Ayuso RM, Arroyo V, Planas R, et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin - aldosterone system. Gastroenterology 1983;84:961-8.
13. Santos J, Planas R, Pardo A, et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol 2003;39:187-92. (Pubitemid 36920553)
14. Angeli P, Fasolato S, Mazza E, et al. Combined versus sequential diuretic treatment of ascites in nonazotemic patients with cirrhosis: results of an open randomized clinical trial. Gut 2010;59:98-104.
15. Ginès P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987;93:234-41. (Pubitemid 17097585)
16. Ruiz-del-Arbol L, Monescillo A, Jiménez W, et al. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997;113:579-86. (Pubitemid 27351786)
17. Ginès P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988;94:1493-502.
18. Ginès A, Fernandez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996;111:1002-10. (Pubitemid 26327603)
19. Boyer TD. Transjugular intrahepatic portosystemic shunt in the management of complications of portal hypertension. Curr Gastroenterol Rep 2008;10:30-5.
20. Jung HS, Kalva SP, Greenfield AJ, et al. TIPS: comparison of shunt patency and clinical outcomes between bare stents and expanded polytetrafluoroethylene stent-grafts. J Vasc Interv Radiol 2009;20:180-5.
21. Lebrec D, Giuily N, Hadengue A, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. J Hepatol 1996;25:135-44. (Pubitemid 26276624)
22. Rossle M, Ochs A, Gulberg V, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000;342:1701-7. (Pubitemid 30354517)
23. Ginès P, Uriz J, Calahorra B, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002;123:1839-47. (Pubitemid 35408308)
24. Sanyal A, Genning C, Reddy RK, et al. The North American Study for Treatment of Refractory Ascites. Gastroenterology 2003;124:634-41. (Pubitemid 36268482)
25. Salerno F, Merli M, Riggio O, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004;40:629-35. (Pubitemid 39265584)
26. D'Amico G, Luca A, Morabito A, et al. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 2005;129:1282-93. (Pubitemid 41446867)
27. Runyon BA. American Association for the Study Liver Diseases. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009;49:2087-107.
28. Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut 2006;55(Suppl 6):vi1-12.
29. Garcia-Tsao G, Lim JK; Members of Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009;104:1802-29.
30. Ginès P, Angelo P, Lenz K, et al; European Association for the Study of the Liver. EASL Clinical Practice Guidelines. Management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397-417.
31. Schrier RW. Vasopressin and aquaporin 2 in clinical disorders of water homeostasis. Semin Nephrol 2008;28:289-96. (Pubitemid 351756521)
32. Guevara M, Baccaro ME, Torre A, et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol 2009;104:1382-9.
33. Häussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008;57:1156-65.
34. Guevara M, Baccaro ME, Ríos J, et al. Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver Int 2010;30:1137-42.
35. Ginès P, Berl T, Bernardi M, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998;28:851-64. (Pubitemid 28405440)
36. Angeli P, Wong F, Watson H, et al. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 2006;44:1535-42. (Pubitemid 44953659)
37. Biggins S, Rodriguez HJ, Bachetti P, et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005;41:32-9. (Pubitemid 40066380)
38. Londoño MC, Cardenas A, Guevara M, et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 2007;56:1283-90. (Pubitemid 47300431)
39. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008;359:1018-26.
40. Yun BC, Kim WR, Benson JT, et al. Impact of pretransplant hyponatremia on outcome following liver transplantation. Hepatology 2009;49:1610-15.
41. Londoño MC, Guevara M, Rimola A, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006;130:1135-43.
42. Dawwas MF, Lewsey JD, Neuberger JM, et al. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl 2007;13:1115-24. (Pubitemid 47305030)
43. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-112. (Pubitemid 44749318)
44. Ginès P, Wong F, Watson H, et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial. Hepatology 2008;48:204-13.
45. O'Leary JG, Davis GL. Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease. Liver Transpl 2009;15:1325-9.
46. Salerno F, Gerbes A, Wong F, et al. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. A consensus workshop of the international ascites club. Gut 2007;56:1310-18. (Pubitemid 47300435)
47. Ginès A, Escorsell A, Ginès P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-36. (Pubitemid 23234041)
48. Fasolato S, Angeli P, Dallagnese L, et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 2007;45:223-9. (Pubitemid 46144382)
49. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-9. (Pubitemid 29362513)
50. Sigal SH, Stanca CM, Fernandez J, et al. Restricted use of albumin for spontaneous bacterial peritonitis. Gut 2007;56:597-9. (Pubitemid 46580522)
51. Fernández J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818-24. (Pubitemid 47374144)
52. Lebrec D, Thabut D, Oberti F, et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010;138:1755-62.
53. Gluud LL, Christensen K, Christensen E, et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010;51:576-84.
54. Uriz J, Ginès P, Cardenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33:43-8. (Pubitemid 30418933)
55. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923-30. (Pubitemid 34267275)
56. Solanki P, Chawla A, Garg R, et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003;18:152-6. (Pubitemid 36349860)
57. Halimi C, Bonnard P, Bernard B. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002;14:153-8. (Pubitemid 34163994)
58. Sanyal A, Boyer T, Garcia-Tsao G, et al. A prospective, randomized, double blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Gastroenterology 2008;134:1360-8. (Pubitemid 351615358)
59. Martin-Llahi M, Pepin MN, Guevara G, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352-9. (Pubitemid 351626950)
60. Triantos CK, Samonakis D, Thalheimer U, et al. Terlipressin therapy for renal failure in cirrhosis. Eur J Gastroenterol Hepatol 2010;22:481-6.
61. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-7. (Pubitemid 29247040)
62. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55-64. (Pubitemid 38868923)
63. Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenaline and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology 2002;36:374-80. (Pubitemid 34810356)
64. Guevara M, Ginès P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998;28:416-22. (Pubitemid 28363668)
65. Bañares R, Nevens F, Larsen FS, et al. Extracorporeal liver support with the molecular adsorbent recirculating system (MARS) in patients with acute-on-chronic liver failure (AOCLF). The RELIEF Trial. J Hepatol 2010;52:1184A.
66. Rifai K, Kribben A, Gerken G, et al. Extracorporeal liver support by fractionated plasma separation and adsorption (Prometheus®) in patients with acute-on-chronic liver failure (Helios study): a prospective randomized controlled multicenter study. J Hepatol 2010;52:6A.
67. Charlton MR, Wall WJ, Ojo AO, et al. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl 2009;15:S1-34.
68. Fernández J, Navasa M, Gómez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002;35:140-8. (Pubitemid 34032554)
69. Acevedo J, Fernandez J, Castro M, et al. Current recommended empirical antibiotic therapy in patients with cirrhosis and bacterial infection. J Hepatol 2009;50:6A.
70. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000;32:142-53. (Pubitemid 30039459)
71. Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:495-501.
72. Saab S, Hernandez JC, Chi AC, et al. Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis. Am J Gastroenterol 2009;104:993-1001.
73. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double blind, placebo-controlled trial. Hepatology 1990;12:716-24. (Pubitemid 20349256)
74. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, et al. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010 Sep 8;(9):CD002907.
75. Bernard B, Grangé JD, Nguyen K, et al. Antibiotics prophylaxis in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999;29:1655-61. (Pubitemid 29247035)
76. Fernández J, Ruiz del Arbol L, Gomez C, et al. Norfloxacin versus ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006;131:1049-56. (Pubitemid 44498687)
77. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716-21. (Pubitemid 34183979)
78. Bajaj JS. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther 2010;31:537-47.
79. Butterworth R. Pathogenesis of hepatic encephalopathy: new insights from neuroimaging and molecular studies. J Hepatol 2003;39:278-85. (Pubitemid 36920567)
80. Cordoba J, Lopez-Hellin J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004;41:38-43. (Pubitemid 39005150)
81. Blei AT, Cordoba J. Practice Parameters Committee of the American College of Gastroenterology Hepatic Encephalopathy. Am J Gastroenterol 2001;96:1968-76.
82. Sharma BC, Sharma P, Agrawal A, et al. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Gastroenterology 2009;137:885-91.
83. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004;328:1046.
84. Lawrence KR, Klee JA. Rifaximin for the treatment of hepatic encephalopathy. Pharmacotherapy 2008;28:1019-32.
85. Jiang Q, Jiang XH, Zheng MH, et al. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2008;20:1064-70.
86. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010;362:1071-8.
87. de Franchis R, Primignani M. Natural history of portal hypertension in patients with cirrhosis. Clin Liver Dis 2001;5:645-63. (Pubitemid 32847054)
88. Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010;362:823-32.
89. Zaman A, Hapke R, Flora K, et al. Prevalence of upper and lower gastrointestinal tract findings in liver transplant candidates undergoing screening endoscopic evaluation. Am J Gastroenterol 1999;94:895-9. (Pubitemid 29173598)
90. Carbonell N, Pauwels A, Serfaty L, et al. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004;40:652-9. (Pubitemid 39265587)
91. D'Amico G, de Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003;38:599-612.
92. Goulis J, Armonis A, Patch D, et al. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998;27:1207-12. (Pubitemid 28227845)
93. Ben-Ari Z, Cardin F, McCormick AP, et al. A predictive model for failure to control bleeding during acute variceal haemorrhage. J Hepatol 1999;31:443-50. (Pubitemid 29408726)
94. Abraldes JG, Villanueva C, Banares R, et al. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol 2008;48:229-36.
95. Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004;40:793-801. (Pubitemid 39288111)
96. Garcia-Tsao G, Sanyal AJ, Grace ND, et al; Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46:922-38.
97. de Franchis R. Evolving consensus in portal hypertension: report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43:167-76.
98. Albillos A, Penas B, Zamora J. Role of endoscopy in primary prophylaxis for esophageal variceal bleeding. Clin Liver Dis 2010;14:231-50.
99. Norberto L, Polese L, Cillo U, et al. A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation. Liver Transpl 2007;13:1272-8. (Pubitemid 47457054)
100. Tripathi D, Graham C, Hayes PC. Variceal band ligation versus beta-blockers for primary prevention of variceal bleeding: a meta-analysis. Eur J Gastroenterol Hepatol 2007;19:835-45. (Pubitemid 47415141)
101. Cardenas A, Gines P, Uriz J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 2001;34:671-6. (Pubitemid 32927990)
102. Levacher S, Letoumelin P, Pateron D, et al. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 1995;346:865-8.
103. Ioannou G, Doust J, Rockey DC. Terlipressin for acute variceal hemorrhage. Cochrane Database Syst Rev 2003:CD002147.
104. Escorsell A, Ruiz del Arbol L, Planas R, et al. Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology 2000;32:471-6.
105. Corley DA, Cello JP, Adkisson W, et al. Octreotide for acute esophageal variceal bleeding: a meta-analysis. Gastroenterology 2001;120:946-54. (Pubitemid 32193191)
106. Cárdenas A. Management of acute variceal bleeding: Emphasis on endoscopic therapy. Clin Liver Dis 2010;14:251-62.
107. Garcia-Pagan JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010;362:2370-9.
108. Avgerinos A, Klonis C, Rekoumis G, et al. A prospective randomized trial comparing somatostatin, balloon tamponade and the combination of both methods in the management of acute variceal haemorrhage. J Hepatol 1991;13:78-83.
109. Banares R, Casado M, Rodriguez Laiz JM, et al. Urgent transjugular Intrahepatic portosystemic shunt for control of acute variceal bleeding. Am J Gastroenterol 1998;93:75-9. (Pubitemid 29065518)
110. Sanyal AJ, Freedman AM, Luketic VA, et al. Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Gastroenterology 1996;111:138.
111. Henderson JM, Boyer TD, Kutner MH, et al. Distal splenorenal shunt versus transjugular intrahepatic portal systematic shunt for variceal bleeding: a randomized trial. Gastroenterology 2006;130:1643-51. (Pubitemid 43668831)
112. Henderson JM. Salvage therapies for refractory variceal hemorrhage. Clin Liver Dis 2001;5:709-25. (Pubitemid 32847057)
113. Gonzalez R, Zamora J, Gomez-Camarero J, et al. Meta-analysis: Combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med 2008;149:109-22. (Pubitemid 352008598)
114. Seewald S, Ang TL, Imazu H, et al. A standardized injection technique and regimen ensures success and safety of N-butyl-2-cyanoacrylate injection for the treatment of gastric fundal varices (with videos). Gastrointest Endosc 2008;68:447-54.